Literature DB >> 27339595

The predictors of mortality and secular changes in management strategies in emphysematous gastritis.

Andrew Watson1, Vadim Bul1, Jonas Staudacher1, Robert Carroll1, Cemal Yazici2.   

Abstract

BACKGROUND AND AIMS: Emphysematous gastritis (EG) is caused by invasion of the gastric wall by gas-producing organisms and carries mortality rate up to 60%. Our investigation aimed to determine the predictors of survival and the secular trends in survival rates of subjects with EG.
METHODS: PubMed search was completed to identify previous cases of EG. In addition, we included a recent case from our center. Statistical analysis was completed with two-sided Chi2 tests for categorical data and t-tests for continuous variables using SPSS v. 22.0 (SPSS Inc, Chicago, IL).
RESULTS: Study cohort included 59 adults. Mean age was 55.5 years; mean LOS was 28.6 days, and 44.1% of subjects were female. Subjects who had EG before 2000 had significantly higher rates of exploratory laparotomy compared to subjects who had EG after 2000 (62.5% vs. 22.2%, P=0.002). In contrast, subjects with EG after 2000 had significantly higher rates of EGD (55.6% vs. 18.8%, P=0.003) and lower rates of mortality (33.3% vs. 59.4%, P=0.046) compared to subjects with EG on or before 2000. In multivariate logistic regression analysis, the only independent predictor of mortality was length of stay (P=0.047).
CONCLUSION: We showed that previously reported 60% mortality rate of EG has been reduced to 33.3% for cases reported after 2000. EGD has been utilized more often while surgical interventions are used only in carefully selected cases. Our data suggests that early endoscopic evaluation and optimal medical management can perhaps continue to improve survival in subjects with EG.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27339595     DOI: 10.1016/j.clinre.2016.02.011

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN: 2210-7401            Impact factor:   2.947


  10 in total

1.  Emphysematous gastritis with hepatic portal venous gas: a shift towards conservative management.

Authors:  Fredy Nehme; Kyle Rowe; Imad Nassif
Journal:  BMJ Case Rep       Date:  2017-05-30

2.  Emphysematous Gastritis: A Real Indication for Emergent Surgical Intervention?

Authors:  Sana Riaz; Pujitha Kudaravalli; Sheikh A Saleem; Bishnu Sapkota
Journal:  Cureus       Date:  2020-05-13

3.  Diffuse Arterial Atherosclerosis Presenting With Acute Ischemic Gastritis.

Authors:  Mohamed Osman; Abu-Bekr Mohamed; Ahmed Salim
Journal:  Cureus       Date:  2022-09-13

4.  Emphysematous gastritis: Impressive radiological findings.

Authors:  Myeong Ja Jeong
Journal:  Radiol Case Rep       Date:  2022-09-09

5.  Role Of Conservative Management In Emphysematous Gastritis.

Authors:  Divyesh Reddy Nemakayala; Manoj P Rai; Supratik Rayamajhi; Syed-Mohammed Jafri
Journal:  BMJ Case Rep       Date:  2018-02-23

6.  Emphysematous gastritis due to Sarcina ventriculi infection in a diabetic liver-kidney transplant recipient.

Authors:  Rachel Fanaroff; Eric Goldberg; John C Papadimitriou; William S Twaddell; Barry Daly; Cinthia B Drachenberg
Journal:  Autops Case Rep       Date:  2020-05-06

7.  Emphysematous gastritis after metastatic malignant melanoma: a radiological surprise.

Authors:  Chiak Yot Ng; Firdaus Hayati; Chandran Nadarajan
Journal:  BMJ Case Rep       Date:  2020-09-09

8.  Emphysematous gastritis: A case series of three patients managed conservatively.

Authors:  Hassan Nasser; Tommy Ivanics; Shravan Leonard-Murali; Dania Shakaroun; Ann Woodward
Journal:  Int J Surg Case Rep       Date:  2019-10-07

9.  Fatal Outcome of Emphysematous Gastritis due to Sarcina ventriculi Infection.

Authors:  Anita Savić Vuković; Nives Jonjić; Ana Bosak Veršić; Dražen Kovač; Marko Radman
Journal:  Case Rep Gastroenterol       Date:  2021-11-02

10.  Successful management of emphysematous gastritis with invasive gastric mucormycosis.

Authors:  Digvijoy Sharma
Journal:  BMJ Case Rep       Date:  2020-02-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.